Ataxia Market Report and Forecast 2025-2034

The ataxia market size was valued at USD 37.70 Billion in 2024, driven by intensive research activities to develop effective drugs and therapies across the 8 major markets. The market is expected to grow at a CAGR of 9.72% during the forecast period of 2025-2034, with the values likely to reach USD 95.32 Billion by 2034.

Ataxia Market Overview

Ataxia is a neurological condition characterized by loss of muscle control in the arms and legs of a patient. Lack of balance and coordination often results in trouble walking. The condition can also affect fingers, speech, and eye movements in the patients. Ataxia may appear suddenly due to some head injury, stroke, infections, etc., or develop gradually due to alcohol abuse, hypothyroidism, exposure to certain drugs, etc. It can be sporadic, hereditary, or acquired, with Friedreich ataxia being the most common hereditary form, affecting one in every 50,000 people in the United States.

Ataxia has a prevalence of 26 cases per 100,000 children, while hereditary ataxias affect 10 per 100,000 individuals. The increasing incidence is anticipated to boost the ataxia market share in the forecast period. Moreover, the regions with consanguinity (mating between blood relatives) as a common practice show a high prevalence of the disorder. In addition, a surge in drug approvals by the health authorities and robust research activities to find treatment options are driving the growth of the market.

Surge in Drug Approvals to Offer Advanced Treatment Alternatives

The increasing number of drug approvals by the health authorities to address ataxia-associated morbidities is contributing to the ataxia market growth. In February 2023, the United States Food and Drug Administration (FDA) approved Reata Pharmaceuticals, Inc.'s Skyclarys (omaveloxolone), developed by as the first treatment for Friedreich’s ataxia. The efficacy of the drug was tested in a 48-week randomized, placebo-controlled, and double-blind study of 103 patients with the neuromuscular condition, which yielded positive results.

Skyclarys reached another milestone in December 2023 when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive response to its marketing authorization in the European Union. Upon the approval by the European Commission (EC), Skyclarys will be the first authorized treatment within the region for people aged 16 years or more, which can slow the progression of Friedreich’s ataxia.

Intensive Research Activities to Address Increasing Ataxia Market Demand

As Friedreich’s ataxia is the most common type of inherited ataxia, research activities aimed at finding promising therapeutic treatments are being promoted to reduce ataxia-associated healthcare burden. In April 2023, an investigative study on the role of adenosine (a widely distributed nucleoside in the central nervous system) was conducted to evaluate its role in mitigating mitochondrial impairment in patients with Friedreich’s ataxia. The results demonstrated that adenosine could counter the deleterious effects of mitochondrial dysfunction and oxidative stress by regulating mitochondrial function and biogenesis in the fibroblasts of a patient with Friedreich’s ataxia. The results of the study support adenosine as a potential therapeutic in the treatment of this neuromuscular disease.

Other interventions such as stem cell therapy are also receiving attention from researchers for ataxia treatment. In addition, the treatment of spinocerebellar ataxia with mesenchymal stem cells is under investigation, projected to contribute to boost the market size in the forecast period.

Ataxia Market Segmentation

“Ataxia Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

• Spinocerebellar Ataxias
• Ataxia-Telangiectasia
• Episodic Ataxia
• Others (Multiple System Atrophy (MSA)

Market Breakup by Service

• Treatment
• Diagnosis

Market Breakup by Dosage Form

• Solid
• Liquids
• Others

Market Breakup by Age Group

• Adult
• Child
• Geriatric

Market Breakup by End User

• Hospitals
• Clinics
• Others

Market Breakup by Region

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• China

Ataxia Market Regional Analysis

The United States is anticipated to lead the ataxia market, owing to the presence of prominent biopharmaceutical companies, working to offer better treatment alternatives. In May 2023, a Biohaven Ltd announced the submission of a new drug application (NDA) for troriluzole to the United States FDA. The novel drug was designed to treat Spinocerebellar Ataxia Type 3 (SCA3) in patients.

Europe is also witnessing increased funding and investments by various sectors to accommodate the growing ataxia market demand. In January 2024, Vico Therapeutics B.V., a clinical-stage genetic medication company based in the Netherlands, announced USD 60 million Series B financing. The funding is aimed to support the ongoing Phase 1/2a clinical trial of its intrathecally administered product VO659, designed to treat patients affected with spinocerebellar ataxia type 3 and type 1, among other neurological diseases.

Ataxia Market: Competitor Landscape

In July 2023, a global biotechnology company Biogen Inc. acquired Reata Pharmaceuticals, Inc. to accelerate the commercialization of the drug Skyclarys to patients with Friedreich’s ataxia around the world. Biogen agreed to buy Reata for USD 172.50 per share in cash, equivalent to a total enterprise value of around USD 7.3 billion. The market has been witnessing similar events of collaborations and acquisitions to deliver innovative therapies in the areas of unmet medical needs. Consequently, this is expected to propel ataxia market share in the coming years.

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Novartis AG
• Merck KGaA
• Aurobindo Pharma
• Pfizer Inc
• Sanofi
• Teva Pharmaceutical
• Acorda Therapeutics
• Viatris Inc
• Design Therapeutics Inc
• Lupin
• Apotex Inc
• Biohaven Pharmaceuticals
• Amneal Pharmaceuticals LLC.
• Biovista
• Intrabio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

This product will be delivered within 3-5 business days.